Moderna
MRNA
#1830
Rank
NZ$18.73 B
Marketcap
NZ$47.95
Share price
8.67%
Change (1 day)
-34.32%
Change (1 year)
Moderna, Inc. is an American biotechnology company focused on the discovery and development of messenger RNA-based drugs.

Moderna (MRNA) - Total debt

Total debt on the balance sheet as of September 2025 : NZ$1.27 Billion

According to Moderna 's latest financial reports the company's total debt is NZ$1.27 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Moderna - Total debt on balance sheet (from 2017 to 2025)

Total debt by year

Year Total debt Change
2024-12-31NZ$1.32 B-32.61%
2023-12-31NZ$1.96 B3.99%
2022-12-31NZ$1.89 B40.94%
2021-12-31NZ$1.34 B308.28%
2020-12-31NZ$0.32 B67.13%
2019-12-31NZ$0.19 B293.66%
2018-12-31NZ$49.92 M126.03%
2017-12-31NZ$22.08 M22.4%
2016-12-31NZ$18.04 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Regulus Therapeutics
RGLS
NZ$2.42 M-99.81%๐Ÿ‡บ๐Ÿ‡ธ USA
Merck
MRK
NZ$71.61 B 5,536.78%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
NZ$32.15 M-97.47%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
NZ$2.26 B 78.26%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
NZ$55.43 B 4,262.67%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Arrowhead Pharmaceuticals
ARWR
NZ$0.61 B-51.90%๐Ÿ‡บ๐Ÿ‡ธ USA
Johnson & Johnson
JNJ
NZ$79.27 B 6,139.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA